SOURCE: IO NewsWire

September 16, 2011 07:00 ET

Unilife Pre-Filled Syringes Are a Game Changer

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire.

NEW YORK, NY--(Marketwire - Sep 16, 2011) - Unilife, Corp (NASDAQ: UNIS) CEO Alan Shortall was interviewed by TheStreet.com on the company's product line, future direction and short positions in the stock. To watch the entire interview, please visit www.thestreet.com/video/11249107/sanofi-deal-giving-unilife-a-shot-says-ceo.html.

Unilife already has a major licensing deal with Sanofi-Aventis (NYSE: SNY) as well as another global pharmaceutical company, but Mr. Shortall points to other companies coming on board in the near future.

Mr. Shortall also discusses the large short position against the company and the inability for them to squeeze the stock price due in part to the continuous stream of positive news the company has had.

Other active stocks are Becton, Dickinson and Co (NYSE: BDX) and Covidien (NYSE: COV).

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information